Does Sunscreen Actually Prevent Melanoma? Reading the One Randomized Trial

Only one randomized controlled trial has ever measured whether sunscreen prevents melanoma, and it points cautiously toward yes. In the Nambour trial in Queensland, Australia, adults assigned to daily sunscreen had about half as many melanomas by ten years after the study ended as those left to their usual habits, though that result sat right at the edge of statistical significance. The reduction in invasive melanoma was larger and did cross the significance threshold, but it rested on a handful of cases. That single trial, valuable as it is, cannot answer the whole question on its own.

Why there is only one trial

Most of what we believe about sunscreen and melanoma comes from observational studies, which follow people who choose to use sunscreen and compare their outcomes to people who do not. Those studies are prone to confounding, because sun-seekers and sun-avoiders differ in skin type, sun exposure, and dozens of other ways. A randomized trial removes that problem by assigning the behavior at random, but running one against a melanoma endpoint is close to impossible. Melanoma is relatively uncommon and takes years to appear, so a trial needs thousands of people followed for a very long time, and it would be hard to justify assigning anyone to avoid sunscreen today.

The Nambour Skin Cancer Prevention Trial is the accident of history that fills this gap. It was designed in the early 1990s to test sunscreen and beta-carotene against the two common keratinocyte cancers, basal-cell and squamous-cell carcinoma. Melanoma was tracked as a secondary outcome, almost incidentally. That origin matters for how much weight the melanoma numbers can bear.

What the trial did

As reported by Green and colleagues in The Lancet in 1999, the trial enrolled 1,621 adults aged 25 to 75, randomly selected from residents of Nambour, a township in subtropical southeast Queensland. Using a two-by-two factorial design, participants were assigned to apply an SPF 15-plus sunscreen daily to the head, neck, arms, and hands, or to use sunscreen at their own discretion, and separately to take 30 mg of beta-carotene or a placebo. The active phase ran from 1992 to 1996.

Over that period, daily sunscreen cut squamous-cell carcinoma tumors by roughly 40 percent (rate ratio 0.61, 95% CI 0.46 to 0.81). It showed no effect on basal-cell carcinoma (rate ratio 1.03, 95% CI 0.73 to 1.46), and beta-carotene did nothing for either cancer. Those findings alone made Nambour a landmark, because they were the first randomized evidence that a topical sunscreen prevents any skin cancer.

The melanoma numbers, read closely

The melanoma result came a decade later. Green and colleagues reported in the Journal of Clinical Oncology in 2011 that, by ten years after the trial closed, 11 new melanomas had been identified in the daily-sunscreen group versus 22 in the discretionary group. That works out to a hazard ratio of 0.50, a 50 percent lower observed rate. The 95% confidence interval, however, ran from 0.24 to 1.02, and the p-value was 0.051.

That interval is the whole story. Because its upper bound is just above 1.0, the data are technically compatible with no benefit at all. The point estimate is genuinely encouraging, but the trial did not have enough melanoma cases to rule out chance by the conventional standard. When results hinge on 33 events split across two groups, small shifts in a few cases swing the entire conclusion.

The invasive melanoma subgroup looks stronger and weaker at the same time. There were 3 invasive melanomas in the sunscreen group and 11 in the discretionary group, giving a hazard ratio of 0.27 (95% CI 0.08 to 0.97). The upper bound falls below 1.0, so this reaches significance. Yet the interval is enormous, spanning a 92 percent reduction at one end and a bare 3 percent at the other, precisely because it is built on 14 total events. A finding that fragile is a reason for interest, not a foundation for certainty. Pre-invasive melanomas showed no clear effect (hazard ratio 0.73, 95% CI 0.29 to 1.81).

How far the finding travels

Even taken at face value, Nambour describes a specific setting. The participants were mostly fair-skinned adults living at a subtropical latitude with intense year-round ultraviolet exposure, which is close to a worst-case environment for skin cancer and therefore a place where any protective intervention has the most room to show a benefit. The product was an SPF 15 formulation, lower than the SPF 30 to 50 sunscreens common today, and the trial measured a habit of daily application to specific body areas rather than the sporadic beach-day use many people actually practice. A review in the British Journal of Dermatology stresses that there is no level-one evidence for a protective effect across all melanomas, and that the trial cannot tell us how consistently sunscreen must be used to prevent the outcomes that matter most, such as metastatic disease or death.

None of this argues against sunscreen. Daily use has randomized evidence behind it for squamous-cell carcinoma, strong observational support for melanoma, and a favorable safety profile. The honest summary is narrower than the headlines: one trial, not built for the question, found a halving of melanoma that was real in direction and borderline in certainty, and no one has repeated it. Good evidence and definitive evidence are not the same thing, and both ideas can be held at once.

This article is educational and is not medical advice; decisions about sun protection and skin-cancer screening should be made with a qualified clinician.